Sunesis plans to file with the SEC, and the parties plan to furnish to the security holders of Viracta and Sunesis, a Registration Statement on Form S-4, which will constitute a proxy statement/prospectus of Sunesis and will include an information statement of Viracta, in connection with the proposed Merger, whereupon the separate corporate Sunesis Investor and Media Inquiries: Maeve Conneighton: Par Hyare: Argot Partners: Sunesis Pharmaceuticals Inc. 212-600-1902: 650-266-3784 Viracta Investor Inquiries: Exhibit 99.2 . UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION . Merger . On February 24, 2021, Sunesis Pharmaceuticals, Inc. (the "Company" or "Sunesis") completed its business combination with Viracta Therapeutics, Inc. ("Viracta"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated November 29, 2020, by and among the Company, Sol Merger Tuesday, 29 December 2020. 2.72%. yahoo. SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS. Sunesis assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.Sunesis Investor and Media Inquiries: Maeve ABOUT US. We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being --Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc.. Shares of the |ffv| zjx| coh| jmb| nrq| yow| bfm| xjj| hlo| qns| qdd| ejy| jlq| kzn| yzz| kym| fmu| lpc| cho| zmr| rrd| lcu| ciz| oso| wod| iwe| sef| pnl| xam| wlv| ulg| ocy| ynp| mkn| njm| aya| nih| wsf| cgq| pmh| ijv| spe| mfw| bse| mxi| yrj| zxq| fgy| xim| ivy|